Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gum disease breakdown? new peptide gel aims to regrow bone

NCT ID NCT07581613

Disease control Sponsor: Siddharth Shanbhag Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new gel made from peptides (protein fragments) to see if it can help regrow bone and tissue damaged by gum disease. Forty adults with advanced periodontitis will receive either the new peptide gel or a standard hyaluronic acid gel during surgery. Researchers will track bone healing and gum attachment over one year to compare safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
proline-rich peptide hydrogel (PeriHeal)
What this could lead to
If it works, this could offer a new option to help regrow bone and tissue lost to gum disease, potentially improving tooth support.
What could go wrong
This is an early Phase 1/2 trial with only 40 people, so results are preliminary. The new hydrogel may not work better than existing treatments, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Adults \>18 years with periodontitis (Stage III or IV) * Systemically healthy (ASA I or II) * Non-smokers or smoking \<10 cigarettes/day * Having undergone steps 1 (risk factor control, oral hygiene improvement including interdental hygiene) and 2 (subgingival instrumentation and biofilm control) of systematic periodontal therapy * Indication for step 3 periodontal therapy, i.e., sites with residual/persistent pockets (PPD \>5 mm and BoP or PPD \>6 mm) around single- or multi-rooted teeth with mobility \<grade II at re-evaluation 8-12 weeks after non-surgical instrumentation (Step 2). Further site-specific criteria include at least one site with a radiographic infrabony defect (2- or 3-walled) with a \>3 mm intrabony component, not associated with an open furcation, indicated for regenerative surgery * Full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) ≤20% before surgery Exclusion criteria * Medical conditions contraindicating surgery * Pregnancy or lactation * Current use of systemic antibiotics * Smoking \>10 cigarettes/day * FMPS or FMBS \>20% * Mobility grade II or greater * Acute oral infections, active endo-perio lesions or active carious lesions on teeth associated with bone defects

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intrabony periodontal defects are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

periodontal disorder periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intrabony periodontal defects Periodontal disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Dentistry, University Complutense of Madrid

    Madrid, Spain

  • Faculty of Dentistry, University of Oslo

    Oslo, 0455, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.